[go: up one dir, main page]

EA201691997A1 - Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы - Google Patents

Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы

Info

Publication number
EA201691997A1
EA201691997A1 EA201691997A EA201691997A EA201691997A1 EA 201691997 A1 EA201691997 A1 EA 201691997A1 EA 201691997 A EA201691997 A EA 201691997A EA 201691997 A EA201691997 A EA 201691997A EA 201691997 A1 EA201691997 A1 EA 201691997A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
nervous system
central nervous
disorders
tiazolinidon
Prior art date
Application number
EA201691997A
Other languages
English (en)
Other versions
EA035866B1 (ru
Inventor
Кольасо Ана Мария Гарсия
Дэвид Джон Аугустус Экланд
Лаланса Мария Пилар Пискуэта
Педемонте Марк Мартинель
Original Assignee
Минорикс Терапьютикс С.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Минорикс Терапьютикс С.Л. filed Critical Минорикс Терапьютикс С.Л.
Publication of EA201691997A1 publication Critical patent/EA201691997A1/ru
Publication of EA035866B1 publication Critical patent/EA035866B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к 5-(4-(2-(5-(1-гидроксиэтил)пиридин-2-ил)этокси)бензил)тиазолидин-2,4-диону и новым стереоизомерам указанного соединения для применения в лечении расстройств центральной нервной системы (НС).
EA201691997A 2014-04-02 2015-04-01 Применение производных 2,4-тиазолидиндиона для лечения расстройств центральной нервной системы и способ лечения с использованием таких производных EA035866B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14382130 2014-04-02
PCT/EP2015/057224 WO2015150476A1 (en) 2014-04-02 2015-04-01 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Publications (2)

Publication Number Publication Date
EA201691997A1 true EA201691997A1 (ru) 2017-02-28
EA035866B1 EA035866B1 (ru) 2020-08-21

Family

ID=50513194

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201691997A EA035866B1 (ru) 2014-04-02 2015-04-01 Применение производных 2,4-тиазолидиндиона для лечения расстройств центральной нервной системы и способ лечения с использованием таких производных
EA202091120A EA202091120A3 (ru) 2014-04-02 2015-04-01 Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202091120A EA202091120A3 (ru) 2014-04-02 2015-04-01 Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы

Country Status (24)

Country Link
US (3) US9782395B2 (ru)
EP (2) EP3125888B1 (ru)
JP (2) JP6745726B2 (ru)
KR (1) KR102418167B1 (ru)
CN (1) CN106470991B (ru)
AU (1) AU2015239112C1 (ru)
CA (1) CA2943373C (ru)
CL (1) CL2016002508A1 (ru)
CY (2) CY1120454T1 (ru)
DK (2) DK3388064T3 (ru)
EA (2) EA035866B1 (ru)
ES (2) ES2872335T3 (ru)
HR (2) HRP20180983T1 (ru)
HU (2) HUE039555T2 (ru)
IL (1) IL248037B (ru)
LT (2) LT3125888T (ru)
MX (1) MX373234B (ru)
NZ (1) NZ725492A (ru)
PL (2) PL3125888T3 (ru)
PT (2) PT3125888T (ru)
SG (1) SG11201608218QA (ru)
SI (2) SI3125888T1 (ru)
WO (1) WO2015150476A1 (ru)
ZA (1) ZA201607286B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
CA2941562C (en) 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
EP3666273A3 (en) 2014-01-15 2020-10-28 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
MX373234B (es) * 2014-04-02 2020-05-08 Minoryx Therapeutics S L Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central.
JP7040798B2 (ja) 2016-12-01 2022-03-23 ミノリックス セラピューティクス エセ．エレ． 非アルコール性脂肪性肝疾患を処置するための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオン
EP3559010B1 (en) * 2016-12-23 2022-06-08 Minoryx Therapeutics S.L. Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof
EP3801516A1 (en) * 2018-06-06 2021-04-14 Minoryx Therapeutics S.L. Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
JP7510170B2 (ja) * 2018-06-06 2024-07-03 ミノリックス セラピューティクス エセ．エレ． ５－［［４－［２－［５－アセチルピリジン－２－イル］エトキシ］ベンジル］－１，３－チアゾリジン－２，４－ジオンおよびその塩の使用
FI3801515T3 (fi) 2018-06-06 2025-05-27 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-hydroksietyyli)pyridin-2-yyli]etoksi]fenyyli]metyyli]-1,3-tiatsolidiini-2,4-dionia ja sen suoloja käytettäviksi mitokondriosairauksien hoidossa
IL297771A (en) 2020-04-30 2022-12-01 Minoryx Therapeutics S L Leriglitazone for treating lung inflammation and interstitial lung disease
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
WO2024141951A1 (en) 2022-12-28 2024-07-04 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone
WO2024231881A2 (en) 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
SK109993A3 (en) * 1991-04-11 1994-12-07 Upjohn Co Thiazolidinedione derivatives producing and use thereof
WO1993022445A1 (en) * 1992-05-05 1993-11-11 The Upjohn Company A process for producing pioglitazone metabolite
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
AU2002367154A1 (en) 2001-12-21 2003-07-15 Smithkline Beecham Corporation Dosing regimen for ppar-gamma activators
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
AU2003254146A1 (en) * 2003-07-24 2005-03-07 Case Western Reserve University Methods for the treatment of parkinson's disease
EP2902026B1 (en) 2006-03-16 2017-10-04 Metabolic Solutions Development Company LLC Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
PL2512470T3 (pl) * 2009-12-15 2017-06-30 Octeta Therapeutics, Llc Oszczędzające ppar tiazolidynodiony i połączenia do leczenia chorób neurodegeneracyjnych
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
WO2013040419A1 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating hyperprolinemia-associated mental disorders
US8865747B2 (en) * 2012-03-23 2014-10-21 Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) Pioglitazone for use in the treatment of adrenoleukodystrophy
US20140178456A1 (en) 2012-08-30 2014-06-26 Udaya Sankar Devanaboyina Methods and compositions for treating type 2 diabetes and related conditions
CA2941562C (en) * 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
EP3666273A3 (en) 2014-01-15 2020-10-28 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
MX373234B (es) * 2014-04-02 2020-05-08 Minoryx Therapeutics S L Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central.

Also Published As

Publication number Publication date
NZ725492A (en) 2023-06-30
AU2015239112A1 (en) 2016-11-10
CY1124088T1 (el) 2022-05-27
IL248037B (en) 2020-09-30
PT3125888T (pt) 2018-07-20
LT3125888T (lt) 2018-07-10
EA035866B1 (ru) 2020-08-21
MX373234B (es) 2020-05-08
IL248037A0 (en) 2016-11-30
AU2015239112C1 (en) 2020-08-20
EP3125888A1 (en) 2017-02-08
US9782395B2 (en) 2017-10-10
LT3388064T (lt) 2021-05-25
EP3388064B1 (en) 2021-03-10
US20160235729A1 (en) 2016-08-18
JP6745726B2 (ja) 2020-08-26
BR112016022974A2 (pt) 2017-12-26
ZA201607286B (en) 2021-07-28
US20180133202A1 (en) 2018-05-17
DK3125888T3 (en) 2018-06-25
ES2872335T3 (es) 2021-11-02
KR20160145639A (ko) 2016-12-20
CN106470991B (zh) 2020-07-31
HUE055351T2 (hu) 2022-05-28
PL3388064T3 (pl) 2021-07-19
MX2016012687A (es) 2017-04-27
DK3388064T3 (da) 2021-04-19
CY1120454T1 (el) 2019-07-10
CA2943373A1 (en) 2015-10-08
AU2015239112B2 (en) 2020-05-07
CA2943373C (en) 2023-01-10
HUE039555T2 (hu) 2019-01-28
SG11201608218QA (en) 2016-10-28
CN106470991A (zh) 2017-03-01
SI3388064T1 (sl) 2021-08-31
WO2015150476A1 (en) 2015-10-08
EA202091120A3 (ru) 2020-12-30
HRP20210518T1 (hr) 2021-05-14
KR102418167B1 (ko) 2022-07-08
PL3125888T3 (pl) 2018-09-28
EA202091120A2 (ru) 2020-08-31
JP2020117539A (ja) 2020-08-06
HRP20180983T1 (hr) 2018-08-10
EP3388064A1 (en) 2018-10-17
EP3125888B1 (en) 2018-05-23
SI3125888T1 (en) 2018-08-31
CL2016002508A1 (es) 2017-04-21
JP2017511339A (ja) 2017-04-20
ES2678046T3 (es) 2018-08-08
US20190255032A1 (en) 2019-08-22
US10179126B2 (en) 2019-01-15
PT3388064T (pt) 2021-05-14

Similar Documents

Publication Publication Date Title
EA201691997A1 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
EA202092442A3 (ru) Новые гетероциклические производные, применимые в качестве ингибиторов shp2
MX390347B (es) Compuestos de aminotiazol como inhibidores de c-kit.
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
EA201790271A1 (ru) Ингибиторы гликозидазы
MX367918B (es) Compuestos heterociclicos fusionados como inhibidores de proteina quinasa.
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
PH12016501941A1 (en) Use of heterocyclic compounds for controlling nematodes
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
PE20161438A1 (es) Inhibidores de desmetilasa 1 especifica a lisina
EA201500362A1 (ru) Ингибиторы rho-киназы
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
EA201790892A1 (ru) Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина
EA201990400A1 (ru) Соединения и композиции и их применение
EA201791030A1 (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
EA201790206A1 (ru) Новые 2,5-замещенные пиримидины в качестве ингибиторов pde4
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
EA201692474A1 (ru) Производные 1-(циклопент-2-ен-1-ил)-3-(2-гидрокси-3-(арилсульфонил)фенил)мочевины в качестве ингибиторов cxcr2
EA201790209A1 (ru) Новые 2,5-замещенные пиримидины в качестве ингибиторов pde
EP3377105A4 (en) COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
NZ630803A (en) Optically active pde10 inhibitor